SBRT 2016

• Is SBRT replacing systemic therapy? • Or should they be combined? • TOAD trial (Duchesne et al, ASCO 2015): immediate versus delayed ADT at PSA relapse after definitive therapy – HR=0.55 (CI: 0.30-1.00) • CHAARTED- (Sweeney et al NEJM 2015): ADT+docetaxel versus ADT alone in advanced stage hormone sensitive PCa – HR=0.61 (CI: 0.47-0.80) – m-OS: 58 and 44 months, respectively • STAMPEDE (James et al Lancet 2016): SOC+docetaxel versus SOC in advanced stage hormone sensitive PCa – HR=0·78 (CI: 0·66–0·93) • Combination with immune stimulating agents SBRT of prostate cancer and systemic therapies